Dynamics of tumor‐specific cfDNA in response to therapy in multiple myeloma patients

OBJECTIVES: Progress in multiple myeloma treatment allows patients to achieve deeper responses, for which the assessment of minimal residual disease (MRD) is critical. Typically, bone marrow samples are used for this purpose; however, this approach is site‐limited. Liquid biopsy represents a minimal...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Eur J Haematol
Autori principali: Vrabel, David, Sedlarikova, Lenka, Besse, Lenka, Rihova, Lucie, Bezdekova, Renata, Almasi, Martina, Kubaczkova, Veronika, Brožová, Lucie, Jarkovsky, Jiri, Plonkova, Hana, Jelinek, Tomas, Sandecka, Viera, Stork, Martin, Pour, Ludek, Sevcikova, Sabina, Hajek, Roman
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2019
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7065130/
https://ncbi.nlm.nih.gov/pubmed/31763708
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ejh.13358
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi